Related to this, CDK12 and CDK13 inhibition in breast cancer induces immunogenic cell death and enhances PD-1 immunotherapy [65], while on the other hand, defective transcriptional elongation is described to confer immunotherapy resistance for some cancers [66]. This evidence concerns the gene CDK13 and breast carcinoma.